SAR131675: Selective VEGFR-3 Inhibition for Targeting Tumor Angiogenesis and Lymphangiogenesis

Introduction: Redefining the VEGFR-3 Inhibitor Landscape in Cancer and Fibrosis Research

In the evolving field of cancer biology and vascular pathophysiology, the VEGFR signaling pathway has emerged as a linchpin for both tumor angiogenesis and lymphangiogenesis. Among the arsenal of research tools, SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor (SKU: B2301), stands out due to its nanomolar potency, unique selectivity profile, and mechanistic depth. While previous reviews have highlighted SAR131675's utility for dissecting the VEGFC–VEGFR-3 axis in cancer and fibrosis (see this comparative thought-leadership analysis), this article extends the narrative by providing a systems-level, integrative perspective. Here, we focus on how SAR131675 enables advanced interrogation of the tumor angiogenesis pathway, uncovers novel regulatory axes in metabolic liver disease, and offers strategic guidance for next-generation pathway-specific studies.

Mechanism of Action: SAR131675 as a Selective ATP-Competitive VEGFR-3 Inhibitor

Biochemical Profile and Selectivity

SAR131675 is a potent inhibitor of vascular endothelial growth factor receptor 3 (VEGFR-3), exhibiting an IC50 of 23 nM and a Ki of 12 nM against recombinant human VEGFR-3 kinase. Functioning as an ATP-competitive inhibitor, it effectively blocks VEGFR-3 autophosphorylation in HEK cells (IC50 30–50 nM). Its chemical structure confers high specificity: it demonstrates minimal inhibition of VEGFR-1 (IC50 > 3 μM) and VEGFR-2 (IC50 235 nM), and shows no significant activity across 65 kinases, 107 non-kinase enzymes and receptors, or 21 ion channels. This exceptional selectivity mitigates off-target effects and makes SAR131675 an invaluable tool for dissecting the VEGFR-3 signaling pathway.

Cellular and In Vivo Activities

SAR131675 efficiently inhibits lymphatic endothelial cell survival induced by VEGFC (IC50 14 nM) and VEGFD (IC50 17 nM), and suppresses endothelial cell migration triggered by VEGFA (IC50 100 nM) and VEGFC (<30 nM) in human lung microvascular endothelial cells (HLMVEC). In vivo, the compound abrogates lymphangiogenesis and angiogenesis stimulated by FGF2, and demonstrates antitumor efficacy by reducing tumor volume in 4T1 mammary carcinoma mouse models. These properties position SAR131675 not only as a VEGFR-3 inhibitor for lymphangiogenesis research, but also as an advanced tool for angiogenesis studies, tumor growth inhibition, and metastasis research.

Unveiling the VEGFC–VEGFR-3 Axis in Metabolic Liver Disease: Systems Biology Insights

Most prior content has focused on the utility of SAR131675 in traditional cancer and fibrosis models (see mechanistic explorations here). In contrast, we offer a new perspective by integrating recent evidence from hepatic fibrosis and metabolic dysfunction-associated fatty liver disease (MAFLD/NAFLD), where the VEGFC–VEGFR-3 axis orchestrates both vascular remodeling and immune regulation.

SAR131675 in Advanced Hepatic Fibrosis Models

A landmark study (Li et al., Phytomedicine 2026) revealed that SAR131675, alongside the phytochemical naringin, mitigates liver inflammation and fibrosis by inhibiting VEGFC-driven signaling. In a high-fat diet-induced mouse model of non-alcoholic steatohepatitis (NASH), SAR131675 treatment led to downregulation of VEGFC and CCL2/CCR2, reduced infiltration of pro-inflammatory Ly6Chigh monocytes, and promoted a phenotypic switch to reparative Ly6Clow macrophages. These effects underscore the compound's ability to disrupt the hepatocyte–macrophage regulatory axis, thereby attenuating fibrosis progression and metabolic inflammation. The study also demonstrated that hepatocyte-specific Vegfc knockout mice recapitulated the therapeutic effects of SAR131675, highlighting the specificity of the VEGFC–VEGFR-3 pathway in orchestrating liver pathology.

Translational Implications for Pathway-Targeted Therapies

This systems-level mechanism—interfering with VEGFC-mediated crosstalk between hepatocytes and macrophages, and modulating immune cell phenotypes—opens new avenues for targeting metabolic liver diseases with anti-lymphangiogenic agents. Specifically, SAR131675, a selective ATP-competitive VEGFR-3 inhibitor, provides a preclinical blueprint for future drugs aimed at both cancer and metabolic inflammation. Importantly, this approach expands beyond the scope of previous SAR131675 articles, which focused primarily on cell-based and preclinical cancer models (see scenario-driven workflows here), by uncovering the underappreciated immunovascular interface in metabolic disease.

Comparative Analysis with Alternative Approaches

VEGFR-3 Inhibition vs. Pan-VEGFR and Non-Selective Kinase Inhibitors

Unlike broad-spectrum kinase inhibitors or non-selective anti-angiogenic compounds, SAR131675 offers several advantages:

• High selectivity for VEGFR-3, minimizing off-target inhibition of VEGFR-1, VEGFR-2, and unrelated kinases.
• ATP-competitive mechanism that allows precise modulation of VEGFR-3–mediated signaling events, including autophosphorylation and downstream effectors.
• No significant activity against non-kinase enzymes, receptors, or ion channels, reducing experimental confounders and toxicity risks.
• Demonstrated efficacy in inhibiting both lymphatic endothelial cell survival and migration—a dual blockade relevant for both lymphangiogenesis and angiogenesis pathway inhibition.

Compared to alternative methods explored in prior guides (see evidence-driven cell assay optimization here), this article elevates the discussion to a systems and translational context, emphasizing how SAR131675, a VEGFR-3 selective kinase inhibitor, enables advanced studies of tissue remodeling, immune regulation, and disease progression.

Advanced Applications: SAR131675 in Tumor Biology, Metastasis, and Immunovascular Research

Tumor Growth Inhibition and Microenvironment Modulation

SAR131675’s ability to inhibit the VEGFR-3 signaling pathway translates directly to tumor volume reduction in preclinical models. By blocking both angiogenesis and lymphangiogenesis, it impedes not only primary tumor growth but also the formation of metastatic niches. The compound’s dual action, as an anti-lymphangiogenic agent and anti-angiogenic compound, allows researchers to dissect the complex interplay between tumor cells, the vasculature, and the immune microenvironment.

Dissecting the VEGFR-3 Pathway in Metastasis and Immune Cell Trafficking

Beyond inhibiting vascular remodeling, SAR131675 provides a window into how VEGFR-3 signaling governs immune cell recruitment and phenotypic switching—key processes in tumor immune escape and chronic inflammation. This perspective is particularly relevant for researchers investigating the links between lymphangiogenesis, immune modulation, and cancer metastasis, themes that have been underexplored in previous technical guides.

Enabling Next-Generation Pathway-Specific Research

As a preclinical VEGFR-3 inhibitor with no off-target kinase, enzyme, or ion channel activity, SAR131675 is ideally suited for advanced studies requiring clean pathway dissection. This makes it a preferred choice for:

• Characterizing the tumor angiogenesis pathway in genetically engineered mouse models.
• Investigating the lymphangiogenesis pathway in tissue regeneration, fibrosis, and metastatic dissemination.
• Elucidating the impact of VEGFR-3 inhibition on immune cell dynamics, macrophage polarization, and stromal interactions.

For laboratories seeking high specificity and robust experimental reproducibility, the APExBIO SAR131675 kit represents a gold standard, especially when compared to less selective or poorly characterized alternatives.

Practical Considerations: Handling, Storage, and Limitations

Physicochemical Properties: SAR131675 is cell-permeable and supplied as a solid, recommended for storage at -20°C. It is insoluble in DMSO, ethanol, and water, and solutions are not recommended for long-term storage—key considerations for assay planning and reproducibility.

Developmental Status: Despite its promising preclinical profile, SAR131675’s development was discontinued due to adverse metabolic effects observed during preclinical studies. Thus, its application is currently limited to research, mechanistic studies, and preclinical models. This highlights the importance of rigorous pathway validation before clinical translation—a point often underemphasized in previous overviews.

Conclusion and Future Outlook: Systems Biology and Personalized Pathway Inhibition

SAR131675, a selective and ATP-competitive VEGFR-3 inhibitor, stands at the forefront of research into angiogenesis, lymphangiogenesis, and tumor microenvironment modulation. By enabling precise dissection of the VEGFR-3 signaling pathway, it not only advances our understanding of cancer biology but also illuminates emerging therapeutic opportunities in metabolic liver disease and immune regulation. This article has extended beyond previous scenario-based or mechanistic guides by providing a systems-level, translationally relevant narrative that integrates immune, vascular, and metabolic axes.

As research pivots toward precision pathway inhibition and the development of next-generation antitumor agents, SAR131675 offers a critical experimental platform—despite its discontinued clinical development. For researchers seeking to advance the frontiers of tumor angiogenesis pathway research, immune–vascular crosstalk, and metabolic disease modeling, the APExBIO SAR131675 toolset remains indispensable. Future studies will benefit from integrating this compound into multi-omic, in vivo, and immune profiling workflows, ensuring that discoveries at the bench translate into actionable insights for the clinic.